Nerac

Information That Drives Innovation

We’re here to help with your research needs
+1 860 872 7000
Customer Access
  • Home
  • What We Do
    • Innovation Insights and Consulting Practice
    • Regulatory
    • Medical Device and Life Sciences
    • Technology Scouting and Innovation
    • Market Research
    • Intellectual Property
    • Commercialization Services for TTOs and Start-Ups
    • Critical Updates
  • Who We Serve
  • How to Engage
  • Why Nerac?
  • Meet our Team
    • Leadership Team
    • Our Analysts
    • Our Partners
  • Nerac Insights and Publications
    • Articles
    • Case Studies
    • Press Room
    • Videos
    • Webcasts
    • White Papers
  • Contact Us
You are here: Home / Nerac Insights / Nerac Announces the February Issue of the Nerac Strategist

Nerac Announces the February Issue of the Nerac Strategist

Facebook0
Google+0
LinkedIn0
Twitter0

New release offers in-depth business perspectives on industry issues, compliance challenges and commercial opportunities authored by Nerac analysts

Read the full release here.

Related Posts

  • EU Regulatory Compliance
    54
    Issue: The client, a major cardiovascular stent company, wanted to ensure proactively that their intra-aortic balloon pump (IABP) catheters would comply with new EU regulations. Analyst Approach: The Nerac team reviewed over 1,000 publications to identify pertinent clinical research. A meta-analysis was performed on 260 applicable articles. Client Benefit: The analysis validated the efficacy of IABP catheters for certain…
    Tags: analysis, clinical, issue, literature, nerac, read, compliance, evaluations
  • What benefit can clients gain from utilizing Nerac’s market research services?
    52
    Nerac helps identify a $300M market opportunity. Have a question for Kevin? Want to give Nerac a shot? Let us know!  
    Tags: nerac, landscape, analysis, competitive
  • Clinical Literature Evaluations via an Objective Third Party Reviewer: Maintaining Compliance with the EU Medical Directives and Beyond
    51
    By Ron Sills, Nerac Analyst, and Donna Mitchell-Magaldi, Nerac Analyst Originally Published: September 26th, 2014 In 2009, the European Commission released MedDev 2.7.1 Rev.3 “Clinical Evaluation: A Guide for Manufacturers and Notified Bodies” as a supplement to the requirements of the EU Medical Device Directive 93/42/EEC.  In order for medical devices to be marketed in…
    Tags: clinical, literature, compliance, nerac, evaluations, read, published, originally
  • Case Studies
  • White Papers
  • Webcasts
  • Articles
    • Nerac Strategist
    • Energy
    • Food & Nutrition
    • Intellectual Property
    • Regulatory
    • Technology & Innovation
    • Medical Device & Healthcare
    • Pharmaceutical
    • Engineering
    • Market Research
    • Critical Alerts
    • Chemistry/Advanced Materials
  • Press Room

Click here to learn more about….

3d printing advanced materials aerospace Ask Kevin Videos biotech CFDA clinical literature evaluations commercialization strategies competitive intelligence conflict minerals Disruptive Technologies emerging markets energy EU MDR FDA food Industry 4.0 innovation Inspiring Next intellectual property intellectual property strategies IP market analysis market research medical device medical devices nerac Nerac client questions Nerac Strategist notified body audit open innovation Order 650 patenting strategies patent landscape pharmaceutical Post-Market Surveillance R&D regulatory regulatory compliance Robert Beinstein Rosemarie Szostak specialty chemicals Sustainable Development Goals technology scouting XcellR8
  • Facebook
  • Google+
  • Linkedin
  • RSS
  • Twitter
  • YouTube
  • Career Opportunities

Copyright © 2021 Nerac · One Technology Drive · Tolland, CT 06084 · 1.860.872.7000

Sign Up for the Nerac Strategist

Like what you see? Sign up here to receive the Nerac Strategist newsletter, a compilation of analyst insights on rapidly developing industry issues, compliance challenges and commercial opportunities!
  • This field is for validation purposes and should be left unchanged.